Floreo
Virtual-reality therapy platform for autistic and neurodivergent learners, with an investigational FDA pathway for FloreoRx.
What They Do
Floreo develops VR-based therapy content to help neurodivergent children and adults practice communication, social, emotional-regulation, and independent-living skills. Can be used at home or in clinical settings. Pursuing FDA De Novo clearance for FloreoRx (submitted April 2026), with FDA Breakthrough Device Designation received in 2023.
Competitive Position
Floreo is one of the few VR-based autism digital therapeutics pursuing an FDA regulatory pathway rather than positioning purely as a wellness or supplemental tool. The FloreoRx De Novo submission and peer-reviewed research collaboration with Cortica give it a credibility edge in clinical settings. Competes with non-VR autism digital therapeutics (e.g., cognoa) and with traditional ABA and social-skills training approaches.
Funding Rounds
No funding rounds on record for this company.